Clinical Pharmacokinetics and Pharmacodynamics of the Epidermal Growth Factor Receptor Inhibitor Panitumumab in the Treatment of Colorectal Cancer

Despite progress in the treatment of metastatic colorectal cancer (mCRC) in the last 15 years, it is still a condition with a relatively low 5-year survival rate. Panitumumab, a fully human monoclonal antibody directed against the epidermal growth factor receptor (EGFR), is able to prolong survival...

Descripción completa

Detalles Bibliográficos
Autores principales: Ketzer, Sander, Schimmel, Kirsten, Koopman, Miriam, Guchelaar, Henk-Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5856878/
https://www.ncbi.nlm.nih.gov/pubmed/28853050
http://dx.doi.org/10.1007/s40262-017-0590-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5856878/
https://www.ncbi.nlm.nih.gov/pubmed/28853050
http://dx.doi.org/10.1007/s40262-017-0590-9

Ejemplares similares